Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenue:
Product sales	$ 2,052,398	$ 2,197,029	$ 7,758,463	$ 5,820,691
Development revenue	2,606,482	952,557	6,329,967	2,725,275
Licensing revenue	77,284	123,419	812,196	608,445
Royalties	949,753	646,032	2,173,775	1,877,046
Total revenue	5,685,917	3,919,037	17,074,401	11,031,457
Cost of revenue:
Cost of product sales	1,673,849	1,028,376	5,071,007	2,741,783
Cost of development revenue	1,622,640	778,674	2,747,424	1,911,397
Total cost of revenue	3,296,489	1,807,050	7,818,431	4,653,180
Gross profit	2,389,428	2,111,987	9,255,970	6,378,277
Operating expenses:
Research and development	3,900,475	1,429,210	9,260,422	5,124,877
Sales, marketing and business development	457,020	390,260	1,312,614	1,202,127
General and administrative	1,551,147	1,559,018	5,089,744	4,325,699
Total Operating expenses	5,908,642	3,378,488	15,662,780	10,652,703
Operating loss	(3,519,214)	(1,266,501)	(6,406,810)	(4,274,426)
Other income (expense)	(15,025)	(32,758)	(8,895)	40,437
Net loss	$ (3,534,239)	$ (1,299,259)	$ (6,415,705)	$ (4,233,989)
Basic and diluted net loss per common share	$ (0.03)	$ (0.01)	$ (0.06)	$ (0.04)
Basic and diluted weighted average common shares outstanding	108,961,792	103,311,772	105,735,855	94,793,953